FGF receptors (FGFR) are attractive candidate targets for cancer therapy because they are dysregulated in several human malignancies. FGFR2 and FGFR3 can be inhibited potentially without disrupting adult tissue homeostasis. In contrast, blocking the closely related FGFR1 and FGFR4, which regulate specific metabolic functions, carries a greater safety risk. An anti-FGFR3 antibody was redesigned here to create function-blocking antibodies that bind with dual specificity to FGFR3 and FGFR2 but spare FGFR1 and FGFR4. R3Mab, a previously developed monospecific anti-FGFR3 antibody, was modified via structure-guided phage display and acquired additional binding to FGFR2. The initial variant was trispecific, binding tightly to FGFR3 and FGFR2 and moderately to FGFR4, while sparing FGFR1. The X-ray crystallographic structure indicated that the antibody variant was bound to a similar epitope on FGFR2 as R3Mab on FGFR3. The antibody was further engineered to decrease FGFR4-binding affinity while retaining affinity for FGFR3 and FGFR2. The resulting dual-specific antibodies blocked FGF binding to FGFR3 and FGFR2 and inhibited downstream signaling. Moreover, they displayed efficacy in mice against human tumor xenografts overexpressing FGFR3 or FGFR2. Thus, a monospecific antibody can be exquisitely tailored to confer or remove binding to closely related targets to expand and refine therapeutic potential.
Introduction
FGFs and their tyrosine kinase receptors (FGFR) play key roles in regulating specific pathways during embryonic development, as well as homeostasis of diverse tissues, wound-healing processes, and certain metabolic functions in the adult animal. In humans, there are 4 highly homologous FGFRs (FGFR1-4) and 22 FGFs (FGF1-14 and FGF16-23; refs. 1-4). The FGFRs comprise an extracellular region with 3 immunoglobulin domains (D1, D2, and D3), a single-pass transmembrane region, and a split cytoplasmic kinase moiety (1, 5). Alternative splicing gives rise to 2 major variants of FGFR1-3, termed isoforms IIIb and IIIc, which differ in the second half of D3 and consequently in ligand-binding specificity (6) .
Dysregulated signaling by FGFR1-4 is associated with pathogenesis in several cancer types (2, 3) . Genomic FGFR alterations, which include gene amplification, chromosomal translocation, and activating mutations, can drive aberrant activation of the FGF pathway and promote neoplastic transformation of normal cells. FGFR2 gene amplification occurs in about 10% of gastric and about 4% of triple-negative breast cancers (7) (8) (9) , while FGFR3 amplification is associated with specific subsets of bladder cancer (9, 10) . Missense FGFR mutations are also found in multiple types of cancer (2, 11) . Specifically, amino acid substitutions in the linker region between D2 and D3, for example, S252W in FGFR2 and S249C in FGFR3, augment FGF-driven signaling and tumor cell proliferation and represent hotspots for somatic mutation (12, 13) . Activating mutations also occur in the tyrosine kinase region of FGFRs (14) .
Targeting the FGF/FGFR pathway has been a major area of focus for cancer drug development. This effort has included smallmolecule tyrosine kinase inhibitors (TKI), blocking antibodies, as well as ligand traps (9) . Current high-potency FGFR TKIs have limited selectivity for different FGFRs (9) , which may affect their therapeutic window. For example, disruption of FGF23 signaling through heterocomplexes of FGFR1 and the coreceptor Klothob can lead to hyperphosphatemia and soft-tissue calcification in patients (15, 16) , whereas blockade of FGF19 signaling through FGFR4 heterocomplexes with Klothob can disrupt bile acid metabolism (17) . More selective antibodies have been developed to antagonize ligand signaling through individual FGFRs, including FGFR1 (18) , FGFR2 (19) , and FGFR3 (20) . However, antibodies recognizing more than one FGFR have not yet been reported.
The previously described monospecific anti-FGFR3 antibody R3Mab effectively blocks binding of FGF1 and FGF9 to both the IIIb and IIIc isoforms of wild-type FGFR3, as well as to certain cancer-associated mutant forms of FGFR3 (20, 21) . X-ray structural analysis revealed that R3Mab binds to a specific epitope on FGFR3 that is required for ligand binding. R3Mab displayed potent antitumor activity in mice against human bladder cancer and multiple myeloma tumor xenografts. In this study, structureguided phage display was used iteratively to engineer R3Mab into derivative antibodies that carry dual specificity for FGFR3 and FGFR2 while sparing FGFR1 and FGFR4. The aim of this study was to broaden the potential therapeutic scope beyond that of the parent molecule while avoiding added safety risks. The engineered antibodies displayed inhibition of FGF-stimulated tumor cell growth in vitro and significant efficacy against human cancer xenografts overexpressing FGFR2 or FGFR3 in vivo.
Materials and Methods

Generation of FGFR2-binding R3Mab variants by phage library selection
Random mutations were incorporated into each of the CDR loops H1, H2, H3, or L2 (Supplementary Table S1 ) using the method of Kunkel and colleagues (22) . Purified phage suspensions from each library were panned separately against immobilized FGFR2-IIIb proteins for the first round of panning. Eluted phage particles were then pooled together and propagated for subsequent rounds of panning. Ninety-six randomly picked colonies were individually cultured and assayed by phage ELISA to screen for FGFR2 binders. Meanwhile, phagemid DNA was extracted and sequenced from the cultures.
Library construction and selection for FGFR2 binders that do not bind FGFR4
The phage display libraries were constructed on the basis of the phagemid displaying the Fab fragment of antibody 2B.1.3. Selected positions in CDR H1, H3, or L2 loops were subject to random mutagenesis (Supplementary Table S2 ). For selection of clones that have reduced FGFR4 binding while retaining FGFR2 specificity, in the first round, 1.5 OD of each phage library was mixed with 0.5 nmol/L FGFR4-Fc protein. The mixture was then incubated overnight at 4 C with plate-immobilized FGFR2-IIIb. The second round of panning was similar to the first round except that 1.5 OD of phage preparations were mixed with 10 nmol/L FGFR4-Fc. For the third and fourth rounds, 0.5 OD of phage preparations were mixed with 460 nmol/L FGFR4-Fc protein and shaken at room temperature (RT) for 20 minutes before being incubated with coated FGFR2-IIIb. Randomly picked clones were cultured for phage ELISA assays and DNA sequencing as described above.
Phage ELISA-binding assay
A 384-well MaxiSorp plate was coated E25 (control antibody), FGFR2-IIIb-His, FGFR2-IIIc-His, or FGFR4-His in each quadrant. Phage supernatant was added into quadrant after blocking with BSA. Bound phage particles were detected with HRP-conjugated anti-M13 monoclonal antibody (GE Healthcare).
Surface plasmon resonance assay
The binding affinities of R3Mab variants for FGFR antigens were determined using a Biacore T100 (GE Healthcare). Anti-human Fc monoclonal antibody was immobilized onto a CM5 biosensor chip. FGFR antigens of various concentrations were injected over captured R3Mab-derived antibodies. Kinetic analyses were performed using the T100 evaluation software to obtain the kinetic and affinity constants.
Protein expression, purification, and structure determination
The human FGFR2-IIIb ECD (residues 140-369) was expressed as inclusion bodies in Escherichia coli BL21(DE3)pLysS cells. The inclusion bodies were washed and dissolved in 6 mol/L guanidine HCl, 20 mmol/L Tris, pH 8, 10 mmol/L TCEP for in vitro folding using the rapid dilution method. The refolding mixture was concentrated and purified through a heparin affinity column (GE Healthcare), followed by ion exchange chromatography. The 2B.1.3 Fab was expressed and purified as described (20) . The FGFR2 and Fab proteins were mixed together at a molar ratio of 1:1 and diluted to 2 mg/mL for crystallization. Crystals were grown at 20% (w/v) PEG 3350, 0.1 mol/L sodium citrate, pH 5.5, and 0.2 mol/L ammonium sulfate using the vapor diffusion method. Diffraction data were collected with a beam wavelength of 1 Å at the ALS and processed to 2.36 Å. Two complexes were found in an asymmetric unit cell. The final model was validated using the program MolProbity (23) . R work and R free values are 19.8% and 24.4%, respectively. No Ramachandran outliers were detected.
Cell lines
SNU16 and MFM-223Â2.2 cell lines were obtained from an internal cell bank. The cell line RT112 was obtained from ATCC. The cells were cultured in RPMI medium supplemented with 10% FBS. All cell lines are tested for mycoplasma, cross-contamination, and genetically fingerprinted when new stocks are generated to ensure quality and confirm ancestry.
FGF ligand-blocking ELISA
A 96-well MaxiSorp plate was coated with anti-human Fc antibody (Jackson ImmunoResearch Lab). FGFR-Fc fusion proteins were incubated after blocking. The plate was washed before being added with the antibody and FGF ligand mixtures. Bound ligand was detected by subsequent incubations of biotinylated anti-FGF antibodies (R&D Biosystems, #BAF273, #BAF251, #BAF969), streptavidin HRP (Invitrogen), and the TMB substrate.
Immunoblotting
Tumor cells were seeded on tissue culture plates for 24 hours, pretreated with 10 mg/mL anti-FGFR antibodies or control anti-gD antibody, and then stimulated with 25 ng/mL FGF7 (R&D Systems) in the presence of 20 mg/mL heparin (Sigma) for 15 minutes. Total cell lysates were blotted with primary antibodies recognizing various signaling molecules, including phospho-FGFR (Y653/ 654), FGFR2, phospho-FRS2 (Y196), FRS2 (Santa Cruz Biotechnology); phospho-ERK1/2 (T202/Y204), ERK1/2, phospho-AKT (S473), AKT, phospho-HER3 (Y1289), HER3, phospho-PLCg1 (Y783), PLCg1 (Cell Signaling); and b-actin (Sigma).
Xenograft experiments
All procedures were approved by and conformed to the guidelines and principles set by the Institutional Animal Care and Use Committee of Genentech and were carried out in an AAALACaccredited facility. SNU-16 tumor fragments of about 15 to 30 mm 3 were implanted subcutaneously into the right flanks of 6-to 8-week-old female Balb/c nude mice (Shanghai Laboratory Animal). Seven million RT-112 bladder carcinoma cells suspended in HBSS with Matrigel were inoculated subcutaneously in the 6-to 8-week-old female C.B-17 SCID mice (Charles River Laboratories). When the mean tumor volume reached 100 to 200 mm 3 (day 0), mice were randomized into groups of 10 and treated starting on day 1 with twice weekly intraperitoneal injections of 2B.1.3.10, 2B.1.3.12, or R3Mab (30 or 50 mg/kg). Control groups were treated with a control human IgG1 antibody diluted in PBS (30 mg/kg). The tumor volumes were measured twice a week.
Statistical analysis
Xenograft data are expressed as mean tumor volumes AE SEM. Unpaired, two-tailed t tests were performed to assess the statistical significance between the experimental and control groups. Time points with P < 0.005 are considered as significant and marked with asterisks.
Complete details of Materials and Methods are provided in Supplementary Data.
Results
Broadening the binding specificity of an anti-FGFR3 antibody
The objective of this study was to develop an antibody with dual specificity for FGFR3 and FGFR2 but sparing the highly related receptors, FGFR1 and FGFR4, as a potential cancer therapeutic. The starting point for this study was the monospecific antibody R3Mab, which binds to the FGFR3-IIIb and IIIc isoforms with sub-nanomolar affinities (20) . R3Mab shows robust inhibition of FGFR3 signaling and tumor growth in vivo (20) and has been studied in phase I clinical trials.
Our antibody redesign strategy was guided by the previously determined crystallographic structure of the R3Mab Fab fragment in complex with FGFR3-IIIb (PDB 3GRW; ref. 20) . This structure indicates that R3Mab interacts with both the D2 and D3 domains of FGFR3-IIIb. Although D2 was subsequently found here to be sufficient for R3Mab binding (see below), initial analyses were based on the contacts within this original structure. Most of the contact surface on the FGFR3-IIIb antigen was contributed by the antibody complementarity-determining regions (CDR) H3 (46%), H1 (23%), and L2 (22%), with small contributions from CDR H2 and framework region (FR) residues (ref. Fig. S1B ). In addition, the D2D3 regions of these 2 homologs share 68% of protein sequence identity, whereas their D2 domains share 76% identity (Supplementary Table S3 ). Because D3 of the R3Mab-bound FGFR3-IIIb had a different geometry as compared with all other FGFR structures (20) , the structures of FGFR2-IIIb and FGFR3-IIIb were superimposed on their D2 regions, which yielded a calculated root mean squared deviation (RMSD) of a-carbon atoms of 0.78 Å. This high degree of structural similarity suggested that it might be feasible to engineer R3Mab to bind and inhibit FGFR2 as well.
To construct a phage display library, mutations were designed that cover most residues in each of the individual heavy-chain CDRs and a selection of the contact residues on all CDRs (Supplementary Table S1 ). R3Mab variants displayed as Fab fragments on phage particles were selected for binding to FGFR2-IIIb. Selection on FGFR3 was not performed at this stage to keep the selection stringency low when recruiting binding to FGFR2. After the first round of panning, the phage outputs from the individual libraries were combined and subjected to 3 further rounds of selection. Ninety-five antibody clones, designated as the 2B.1 series, were screened by phage ELISA-binding assay. Among these, 81 clones, representing 32 unique sequences, bound to FGFR2-IIIb. All binding clones were apparently derived from the H2 library because they contained mutations in CDR H2 but not elsewhere (Table 1) . The 32 unique antibodies were expressed and purified as corresponding IgG1 molecules. All of them showed substantially improved binding to FGFR2-IIIb relative to R3Mab, with K D values ranging from 0.3 to 17 nmol/L (Table 1) . Remarkably, the mutated H2 sequences contain significant variation, lack clear consensus, and differ from R3Mab at 4 or 5 positions (Table  1 , Supplementary Fig. S2 ). Thus, there appear to be multiple possible solutions to conferring high-affinity binding of FGFR2-IIIb onto R3Mab.
Next, 6 variants were selected for measurements of binding to FGFR3 on the basis of their affinities (K D < 3 nmol/L) for FGFR2 and sequence diversity. All the variants showed improved affinities for FGFR3-IIIb (Supplementary Table S4 ). To further assess their ability to inhibit receptor-dependent cell growth, proliferation of MCF7 breast carcinoma cells was assayed either with or without FGF7-a specific ligand for FGFR2-IIIb (1, 19). Variant 2B.1.3 exhibited the greatest antagonistic activity, as compared with other variants, which showed less or no inhibition, or even displayed stimulatory effects (Fig. 1) . Hence, 2B.1.3 was carried over as a functional antibody for further characterization.
Because all FGFR homologs share nearly 70% sequence identity between each other (Supplementary Table S3 ), the engineered To obtain direct insight into how the engineered variant 2B.1.3 acquired specificity for FGFR2, the crystal structure of its complex with FGFR2 was determined (Fig. 2, Supplementary Table S5 ). FGFR2-IIIb D2D3 was first generated by expression in E. coli and refolding from inclusion bodies and judged to be intact by SDS-PAGE and mass spectrometry. However, in crystals, this protein contained only the isoform-independent D2 domain, suggesting proteolysis between D2 and D3 during the crystallization process. The previously determined FGFR3-IIIb:R3Mab complex structure contains both the D2 and D3 domains of FGFR3-IIIb. The whole complex of FGFR2-D2:Mab 2B.1.3 superimposed closely onto the FGFR3-IIIb:R3Mab structure ( Supplementary Fig. S3) , with an overall a-carbon RMSD of 1.4 Å, indicating that the engineering retained the same binding geometry as the original antibody R3Mab. The FGFR3:R3Mab crystal structure suggests considerable interactions between FGFR3 D3 and the CDR H1 loop. Therefore, to investigate the involvement of D3 in binding, proteins of the D2 domains of FGFR2 and FGFR3 were prepared and their binding affinity to R3Mab and Mab 2B.1.3 measured. Only very minor differences in binding affinity between D2 alone and the D2D3 domains were observed for both receptors (Supplementary  Table S6 ). Thus, D2 is primarily responsible for binding of R3Mab and its derivatives, whereas D3 plays a minimal role.
The CDR H2 sequence in Mab 2B.1.3, THLGD, is completely different from the parental H2 sequence in R3Mab, IYPTN. As expected, the conformations of the CDR H2 loops in the 2 Mabs differ substantially (Fig. 2C) . Upon aligning the variable domains of Mab 2B.1.3 onto those of R3Mab (Fig. 2B) , the H3 loop also appears twisted by a few degrees, resulting in a distance of 2.6 Å between the Ca atoms of the H3 tip residue Y100b in both structures (Fig. 2C) . Accordingly, the position of the FGFR2 D2 domain overall is shifted by about 3 Å from that of the FGFR3 D2 domain. Comparison of the interface between the variants and the FGFR antigens revealed that such reorganizations of the H2 and H3 CDR loops in Mab 2B.1.3 significantly improved packing against the FGFR2 surface. In the parental structure, the shape complementarity score between R3Mab and FGFR3-D2 is 0.731. If the D2 domain of FGFR2 is aligned onto and replaces FGFR3 D2, the shape complementarity score between R3Mab and FGFR2 D2 drops to 0.685. This might explain the lack of R3Mab binding to FGFR2 (Table 2 ). However, in the new crystal structure, the shape complementarity score between 2B.1.3 and FGFR2-D2 dramatically increased to 0.768, which is consistent with the gain of high-affinity binding to FGFR2 through engineering of R3Mab.
Because of the remarkable similarity among FGFRs, 2B.1.3 cross-reacts with multiple homologs in the family. Although FGFR1 binding was not acquired along with FGFR2 binding, FGFR4 interaction was. Considering that FGFR4 inhibition carries an increased risk of toxicity (17), a second round of engineering was undertaken to eliminate FGFR4 binding.
Further engineering to remove FGFR4 binding
To generate a Mab 2B.1.3 derivative that binds FGFR2 and FGFR3 but not FGFR4, it seemed useful to identify antigen residues that likely interact with the antibody but differ between the various FGFRs (Supplementary Table S7 ), assuming that Mab 2B.1.3 recognizes all FGFRs in an analogous mode to its interaction with FGFR2. Three phage display libraries were constructed on the basis of the 2B.1.3 Fab template, with random mutagenesis at selected positions on the contacted CDRs H1, H3, and L2 (Supplementary Table S2 ). During engineering, the focus was on binding to FGFR2 instead of maintaining both FGFR2 and FGFR3, as in the previous engineering. Therefore, selection was undertaken with immobilized FGFR2-IIIb alone during panning. Table S8 ). Characterized clones from the H3/L2 libraries 2B.1.3.2, 2B.1.3.4, and 2B.1.3.6 contained mutations only in CDR H3, not CDR L2, whereas characterized clones from the H1/H3 library 2B.1.3.8, 2B.1.3.10, and 2B.1.3.12 contained mutations in both CDR H1 and H3. Although the 4 residues in H3 from L100a to D100d were fully randomized, Y100b remained unchanged, suggesting that the interaction of Y100b with FGFR2 is crucial for binding. In addition, L100a was conservatively mutated to Thr or Ile and V100c mostly to Asp. The H1/H3 mutants containing an additional H1 mutation of T28P displayed slightly higher affinities for FGFR2. These antibodies bound FGFR2 with K D values of 1.4 to 6.6 nmol/L but showed minimal binding to FGFR4 when using concentrations as high as 1 mmol/L for measurements, except that clone 2B.1.3.8 still retained detectable yet weak affinity for FGFR4 (Supplementary Table S8 ). The convergence in both sequences and affinities of the 2B.1.3 variants indicated that the last rounds of phage selection had reached the limit of enrichment for binders with desired functions, that is, diminished FGFR4 binding and retention of tight FGFR2 binding.
Considering that greater differential in binding to FGFR2 and FGFR4 as well as fewer mutations are preferable, Mab 2B.1.3.10 and 2B.1.3.12 were selected for further characterization. Both antibodies showed no binding to FGFR1 and retained strong binding to FGFR3 with affinities slightly weaker than 2B.1.3 (Table 2 ). Therefore, after the second-step engineering, the 2B.1.3 derivatives Mab 2B.1.3.10 and 2B.1.3.12 cross-react with FGFR2 and FGFR3 but show no detectable binding to FGFR4.
Next, the abilities of the R3Mab variants to block FGF ligand binding to the specific FGFRs were evaluated. R3Mab blocks FGF ligand binding to both the FGFR3-IIIb and FGFR3-IIIc isoforms. Owing to their different specificities for different FGFRs, the blocking spectrum of each of the new antibodies varied (Fig. 3) .
All the engineered antibodies showed blocking activities for both FGFR2 and FGFR3, whereas R3Mab did not inhibit FGF7 binding to FGFR2-IIIb or FGF1 binding to FGFR2-IIIc. Whereas 2B.1.3 strongly inhibited FGF19 binding to FGFR4, 2B.1.3.10 and 2B.1.3.12 did not block the latter interaction, due to substantially diminished FGFR4 affinity.
Redesigned Mab variants inhibit FGFR2-or FGFR3-dependent tumor cell growth
The newly redesigned variants 2B.1.3.10 and 2B.1.3.12 display dual specificity for FGFR2 and FGFR3. To investigate their biologic activities, their effects on receptor-dependent signaling and proliferation in different types of tumor cells were examined. First, the new variants were assessed for inhibition of growth of FGFR2-overexpressing tumor cells in vitro. Both the SNU-16 gastric carcinoma and MFM-223Â2.2 triple-negative breast carcinoma cell lines have amplification of FGFR2, evident by increased FGFR2 gene copy numbers and protein overexpression (7) . In SNU-16 cells, 2B.1.3.10 and 2B.1.3.12 substantially suppressed FGF7-induced FGFR2 phosphorylation. In addition, the two 2B.1.3 variants markedly reduced phosphorylation of the downstream signaling molecules FRS2a, MAPK, PLCg1, and AKT (Fig. 4A) . Similarly, both variants diminished phosphorylation of FGFR2, FRS2a, MAPK, and HER3 in FGF7-treated MFM-223Â2.2 cells (Supplementary Fig. S4A) .
Next, the ability of the dual-specific Mab 2B.1.3.10 and 2B.1.3.12 to inhibit in vivo FGFR2-dependent and/or FGFR3-dependent growth of tumor xenografts was investigated. The RT112 cell line expresses FGFR3 but not FGFR2. As anticipated, both Mab 2B.1.3.10 and 2B.1.3.12, which retained the parental specificity for FGFR3 after engineering, as well as the parental antibody R3Mab, suppressed the growth of FGFR3-overexpressing RT112 tumor xenografts (Fig. 4B) . The engineered variants 2B.1.3.10 and 2B.1.3.12, with tumor growth inhibition (TGI) values of 48% and 64%, displayed weaker potency than the parental R3Mab (TGI 82%), which could be possibly due to modified pharmacokinetics. For FGFR2-based efficacy, we turned to the SNU-16 cell line, which expresses readily detectable FGFR2 along with very low FGFR3 levels. Mice bearing SNU-16 xenografts were dosed with nonspecific IgG control antibody, the parental R3Mab, or the engineered variants 2B.1.3.10 or 2B.1.3.12. The engineered variants displayed similar TGI values of 63% and 61%, respectively (Fig. 4C) . Surprisingly, R3Mab, although not binding to FGFR2, also showed a measurable TGI of 44%. The tumor samples were then collected and analyzed for FGFR2 and FGFR3 expression (Supplementary Fig. S5 ). FGFR3 was upregulated in the SNU-16 tumor xenografts in vivo, which may explain the observed inhibitory effect of R3Mab in this model. Regardless, the engineered variants showed significantly stronger activity as compared with R3Mab (P < 0.001, day 31). In another experiment, 2B.1.3.10 and 2B.1.3.12 also retarded the growth of MFM-223Â2.2 tumor xenografts in mice (Supplementary Fig. S4B ). Thus the engineered antibodies can serve as dual agents to effectively inhibit both FGFR2-and FGFR3-dependent cancer cell growth.
Discussion
The FGFR family is associated with versatile normal biologic functions and is additionally implicated in a number of cancer malignancies (2, 3) . R3Mab, an antibody that binds monospecifically to FGFR3, was tailored here for binding to other FGFR family members through multiple rounds of engineering, including recruiting desired binding to FGFR2 and removing undesired binding to FGFR4. The first step of engineering was carried out to recruit FGFR2 binding. Each phage library constituted mutagenesis of one contacting CDR, and the range of mutagenesis covered as many residues in that CDR as allowed by library size. Choosing multiple consecutive positions for mutagenesis permitted significant freedom in the CDR backbones. Most of the resulting clones that were able to engage FGFR2 harbored all 5 mutations in CDR H2. The crystal structure demonstrated that the full range of mutagenesis was coupled with complete remodeling of the geometry of the CDR loop. The solutions to spatial reorganizations of a CDR are numerous, as evidenced by the identification of diverse H2 mutants that had gained binding to FGFR2. Such a large variety of solutions is not typically seen as outcomes from standard affinity maturation experiments, whereby the recovered sequences usually contain sparse positions on individual CDRs. Therefore, acquiring additional specificity for homologous antigens may require larger mutagenesis freedom than affinity maturation. As a result, undesired specificity may be acquired through the process, such as the FGFR4 binding in these studies.
The second round of engineering was aimed to refine specificity by removing unwanted FGFR4 binding. Detailed structural analysis of contact residues between the antibody CDR loops and the antigen surface was used to guide the design of phage display libraries. Selected antibody variants showed reduction in unwanted FGFR4 binding with retention of binding to FGFR2/3. The sequence solutions to this step were much more limited as compared with the first round of engineering. No large backbone conformational changes would be expected at this stage. The refinement step further demonstrated the ability to exquisitely differentiate binding specificities among closely related antigens during antibody engineering.
The dual-specific antibodies generated here bind to 2 closely related antigens, namely FGFR2 and FGFR3. These 2B.1.3 antibody variants are regular IgG molecules in that they use identical heavy and light chains for the two antigen-binding fragments. They can potentially bind to 2 FGFR2 isoforms, 2 FGFR3 isoforms or 1 FGFR2 and 1 FGFR3 isoform in a bivalent or monovalent manner, respectively. This contrasts to conventional bispecific IgG, which commonly use two different heavy/ light-chain pairs to bind to 2 different antigens in a monovalent manner. The dual-specific antibodies described herein share some similarities with "two-in-one" antibodies (24). Bostrom and colleagues randomized all 3 light-chain CDRs of herceptin and selected for a second specificity as well as the parental specificity. As expected, the second specificity comes from the dominant contributions of light-chain CDRs (24, 25) . In one case, although EGFR and HER3 are homologous, the binding epitopes by an anti-EGFR/HER3 "two-in-one" antibody are different (25) . The approach described here differs from "two-in-one" antibodies in that it appreciates the sequence and structure similarities between the 2 homologous antigens and focuses on a more limited set of mutagenesis so as to retain the parental epitope during engineering.
The antibody engineering presented here started from an existing and extensively characterized antibody, R3Mab, that has potential use for cancer therapy. Since introduction of the first therapeutic monoclonal antibody in the mid-1980s, there have been many clinically and commercially successful antibody drugs in different disease areas, including trastuzumab, cetuximab, adalimumab, bevacizumab, etc. These antibodies displayed exceptional activities in inhibiting their molecular targets. On the other hand, like the FGFR family, multiple homologous proteins are pursued as molecular targets for their various disease associations. Traditional discovery routes to obtain antibodies targeting a functional epitope, either animal immunization or other display-based library selections, are not guaranteed to be successful. The approach developed here to engineer a known antibody for acquiring specificity toward homologous targets provides an alternative route for antibody discovery. Moreover, it takes advantage of ÃÃÃÃ , P < 0.0001 for 2B.1.3.10 or 2B.1.3.12 versus control MAb at day 22. n ¼ 10 per group; error bars, SEM. C, effect of 2B.1.3.10 and 2B.1.3.12 on the growth of FGFR2-dependent SNU-16 xenografts compared to control antibody and R3Mab. ÃÃÃÃ , P < 0.0001 for 2B.1.3.10 or 2B.1.3.12 versus control MAb at day 28; ÃÃÃ , P < 0.001 for 2B.1.3.10 or 2B.1.3.12 versus R3Mab at day 31. n ¼ 10 per group; error bars, SEM.
the favorable properties of previously developed antibodies by maintaining the functional epitopes and presumably the biologic functions as well. As the clinical antibody repertoire expands, more antibodies could be reengineered instead of being discovered ab initio. Potential applications may include protein families that comprise multiple members as disease targets, such as the EGFR (26), TNFR (27) , TAM (28, 29) , and Eph-Ephrin families (30) . As in the traditional discovery processes, engineered antibodies toward homologs should be considered as new molecules and still need full characterization of their biochemical, biophysical, and biologic properties for any potential therapeutic applications.
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